Andrew Jess Dannenberg

Andrew Jess Dannenberg (born 17 February 1956) is a U.S. physician and former researcher specializing in molecular mechanisms of cancer, formerly associated with Weill Medical College/M.D. Anderson Cancer Center. Beginning in 2020 some of Dannenberg's published papers were retracted due to irregularities with the data or figures.

https://ori.hhs.gov/content/case-summary-dannenberg-andrew

ORI found that Respondent engaged in research misconduct by recklessly reporting falsified and/or fabricated data in the following twelve (12) published papers.

Academic career

Dannenberg received a B.S. from Tufts University in 1978 and an M.D. from Washington University School of Medicine in 1982. In 1988 Dannenberg was hired as an Assistant Professor of Medicine in the Division of Gastroenterology and Hepatology at Weill Medical College, becoming in 2000 the Henry R. Erle, M.D. - Roberts Family Professor of Medicine, and later the Associate Director of Cancer Prevention at the Sandra and Edward Meyer Cancer Center. Dannenberg retired from Weill in 2021.[1] Dannenberg's research at Weill focused upon the molecular mechanisms of cancer and cancer prevention.[2][3][4][5] In 2011 Dannenberg received the AACR-Prevent Cancer Foundation Award for Excellence in Cancer Prevention Research from the American Association for Cancer Research.[6]

Retractions

In 2020, the Journal of Biological Chemistry retracted nine of Dannenberg's publications due to irregularities with the papers' figures.[7] In 2022 an additional nine papers co-authored by Dannenberg were retracted by Cancer Prevention Research due to "evidence of data falsification or fabrication." An investigatory committee at Weill produced findings that were submitted to the federal Office of Research Integrity, with a statement from Dannenberg's attorney reporting that "Dannenberg did not generate the problematic data nor prepare the figures necessitating retraction of any of the nine articles."[8]

As of 2023, Dannenberg has had 20 of his research publications retracted, and two others have received an expression of concern.[9]

References
  1. "What's New in Medicine" (PDF). Weill Cornell Medicine. Weill Cornell Medical College. Retrieved 2023-04-04.
  2. "COX-2 Inhibitors for Cancer Prevention & Treatment: Research Roundup:" by Lindsey, Heather, Oncology Times
  3. "COX-2 Inhibitors: Cancer Trials Test New Uses for Pain Drug" by Jennifer Michalowski, Journal of the National Cancer Institute, 24(4)April 2002, p 52-54
  4. "Researchers Plan To Continue To Study COX-2 Inhibitors in Cancer Treatment and Prevention" by Cori Vanchieri. JNCI Spectrum (with portrait)
  5. "Women who regularly take aspirin at lower risk of breast cancer", Women's Health News, Monday, 31-May-2004
  6. "Prevent Cancer Award". Archived from the original on 2011-09-03. Retrieved 2011-10-15.
  7. Marcus, Adam (3 January 2020). "Prominent cancer researcher loses nine papers, making 10". Retraction Watch. Center for Scientific Integrity. Retrieved 2023-04-04.
  8. Kincaid, Ellie (3 June 2022). "Former Weill Cornell cancer researcher up to 20 retractions; investigation's findings are with Feds". Retraction Watch. Center for Scientific Integrity. Retrieved 2023-04-04.
  9. "Retraction Watch Database". Retraction Watch. Center for Scientific Integrity. Retrieved 2023-04-04.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.